{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:04:35Z","timestamp":1782831875391,"version":"3.54.5"},"reference-count":16,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:00:00Z","timestamp":1625270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diabetes is a rare, but potentially life\u2010threatening, adverse event of immune checkpoint inhibitors that requires prompt recognition and treatment. It usually occurs in the first 3\u2009months of treatment and is typically related to programmed cell death\u20101 antibodies, alone or in combined therapy. It has rarely been described developing after immunotherapy cessation. We present a 51\u2010year\u2010old man with metastatic melanoma, who developed acute\u2010onset diabetes 52\u2009days after combined immunotherapy cessation with nivolumab and ipilimumab, and 25.6\u2009months after receiving the first dose. He presented with acute hyperglycemic symptoms, ketosis, complete insulin depletion and negative autoimmunity, fulfilling the criteria of fulminant type\u20091 diabetes. The patient had previously developed hypophysitis with isolated adrenocorticotropic hormone deficiency during immunotherapy. We describe a case of late\u2010onset fulminant type\u20091 diabetes developing after immunotherapy cessation. Patient education and active follow up after immunotherapy discontinuation are crucial to warrant a timely intervention.<\/jats:p>","DOI":"10.1111\/jdi.13604","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T13:22:52Z","timestamp":1622208172000},"page":"2263-2266","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Onset of fulminant type\u20091 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report"],"prefix":"10.1111","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-4030","authenticated-orcid":false,"given":"Laura","family":"Boswell","sequence":"first","affiliation":[{"name":"Endocrinology and Nutrition Department Hospital Cl\u00ednic of Barcelona Barcelona Spain"},{"name":"Institute of Biomedical Investigations August Pi Sunyer (IDIBAPS), Barcelona, Spain Barcelona Spain"},{"name":"Endocrinology and Nutrition Department Althaia University Health Network Manresa Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregori","family":"Casals","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Investigations August Pi Sunyer (IDIBAPS), Barcelona, Spain Barcelona Spain"},{"name":"Biochemistry and Molecular Genetics Department Hospital Cl\u00ednic of Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Blanco","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department Hospital Cl\u00ednic of Barcelona Barcelona Spain"},{"name":"Institute of Biomedical Investigations August Pi Sunyer (IDIBAPS), Barcelona, Spain Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department Hospital Cl\u00ednic of Barcelona Barcelona Spain"},{"name":"Institute of Biomedical Investigations August Pi Sunyer (IDIBAPS), Barcelona, Spain Barcelona Spain"},{"name":"Centre of Obesity and Nutrition Biomedical Research Network (CIBEROBN) Carlos III Health Institute Madrid Spain"},{"name":"University of Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Aya","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Investigations August Pi Sunyer (IDIBAPS), Barcelona, Spain Barcelona Spain"},{"name":"Medical Oncology Department Hospital Cl\u00ednic of Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"de Hollanda","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department Hospital Cl\u00ednic of Barcelona Barcelona Spain"},{"name":"Institute of Biomedical Investigations August Pi Sunyer (IDIBAPS), Barcelona, Spain Barcelona Spain"},{"name":"Centre of Obesity and Nutrition Biomedical Research Network (CIBEROBN) Carlos III Health Institute Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Halperin","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department Hospital Cl\u00ednic of Barcelona Barcelona Spain"},{"name":"Institute of Biomedical Investigations August Pi Sunyer (IDIBAPS), Barcelona, Spain Barcelona Spain"},{"name":"University of Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M","family":"Arance","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Investigations August Pi Sunyer (IDIBAPS), Barcelona, Spain Barcelona Spain"},{"name":"Medical Oncology Department Hospital Cl\u00ednic of Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Mora","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department Hospital Cl\u00ednic of Barcelona Barcelona Spain"},{"name":"Institute of Biomedical Investigations August Pi Sunyer (IDIBAPS), Barcelona, Spain Barcelona Spain"},{"name":"University of Barcelona Barcelona Spain"},{"name":"Centre of Diabetes and Related Metabolic Diseases Biomedical Research Network (CIBERDEM) Carlos III Health Institute Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia A","family":"Hanzu","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department Hospital Cl\u00ednic of Barcelona Barcelona Spain"},{"name":"Institute of Biomedical Investigations August Pi Sunyer (IDIBAPS), Barcelona, Spain Barcelona Spain"},{"name":"University of Barcelona Barcelona Spain"},{"name":"Centre of Diabetes and Related Metabolic Diseases Biomedical Research Network (CIBERDEM) Carlos III Health Institute Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00006"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14050"},{"key":"e_1_2_6_4_1","first-page":"17","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"26","author":"Bluestone JA","year":"2018","journal-title":"Diabetes"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190019850929"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0291"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2020.09.023"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12024"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2008.05.003"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01402-w"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12531"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00728"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-018-1234-8"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.59125"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.07.021"},{"key":"e_1_2_6_17_1","first-page":"303","article-title":"A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment","volume":"15","author":"Humayun MA","year":"2016","journal-title":"Hormones"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.13604","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdi.13604","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.13604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:18:25Z","timestamp":1693210705000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.13604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,3]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/jdi.13604"],"URL":"https:\/\/doi.org\/10.1111\/jdi.13604","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"value":"2040-1116","type":"print"},{"value":"2040-1124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,3]]},"assertion":[{"value":"2020-10-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}